Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 510

1.

Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial.

Voors AA, Bax JJ, Hernandez AF, Wirtz AB, Pap AF, Ferreira AC, Senni M, van der Laan M, Butler J; PANTHEON Investigators.

Eur J Heart Fail. 2019 Sep 16. doi: 10.1002/ejhf.1591. [Epub ahead of print]

PMID:
31523892
2.

How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).

Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CSP, Lancellotti P, Melenovsky V, Morris DA, Nagel E, Pieske-Kraigher E, Ponikowski P, Solomon SD, Vasan RS, Rutten FH, Voors AA, Ruschitzka F, Paulus WJ, Seferovic P, Filippatos G.

Eur Heart J. 2019 Aug 31. pii: ehz641. doi: 10.1093/eurheartj/ehz641. [Epub ahead of print]

PMID:
31504452
3.

Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study.

Santema BT, Ouwerkerk W, Tromp J, Sama IE, Ravera A, Regitz-Zagrosek V, Hillege H, Samani NJ, Zannad F, Dickstein K, Lang CC, Cleland JG, Ter Maaten JM, Metra M, Anker SD, van der Harst P, Ng LL, van der Meer P, van Veldhuisen DJ, Meyer S, Lam CSP; ASIAN-HF investigators, Voors AA.

Lancet. 2019 Aug 22. pii: S0140-6736(19)31792-1. doi: 10.1016/S0140-6736(19)31792-1. [Epub ahead of print]

PMID:
31447116
4.

Effects of Serelaxin in Patients with Acute Heart Failure.

Metra M, Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Pang PS, Ponikowski P, Voors AA, Adams KF, Anker SD, Arias-Mendoza A, Avendaño P, Bacal F, Böhm M, Bortman G, Cleland JGF, Cohen-Solal A, Crespo-Leiro MG, Dorobantu M, Echeverría LE, Ferrari R, Goland S, Goncalvesová E, Goudev A, Køber L, Lema-Osores J, Levy PD, McDonald K, Manga P, Merkely B, Mueller C, Pieske B, Silva-Cardoso J, Špinar J, Squire I, Stępińska J, Van Mieghem W, von Lewinski D, Wikström G, Yilmaz MB, Hagner N, Holbro T, Hua TA, Sabarwal SV, Severin T, Szecsödy P, Gimpelewicz C; RELAX-AHF-2 Committees Investigators.

N Engl J Med. 2019 Aug 22;381(8):716-726. doi: 10.1056/NEJMoa1801291.

PMID:
31433919
5.

Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study.

Kimmoun A, Cotter G, Davison B, Takagi K, Addad F, Celutkiene J, Chioncel O, Solal AC, Diaz R, Damasceno A, Duengen HD, Filippatos G, Goncalvesova E, Merai I, Metra M, Ponikowski P, Privalov D, Sliwa K, Sani MU, Voors AA, Shogenov Z, Mebazaa A.

Eur J Heart Fail. 2019 Aug 19. doi: 10.1002/ejhf.1575. [Epub ahead of print]

PMID:
31423712
6.

A randomized controlled trial on carbohydrate antigen 125-guided diuretic treatment versus usual care in patients with acute heart failure and renal dysfunction.

Núñez J, Llàcer P, García-Blas S, Bonanad C, Ventura S, Núñez JM, Sánchez R, Fácila L, de la Espriella R, Vaquer JM, Cordero A, Roqué M, Chamorro C, Bodi V, Valero E, Santas E, Del Carmen Moreno M, Miñana G, Carratalá A, Rodríguez E, Mollar A, Palau P, Bosch MJ, Bertomeu-González V, Lupón J, Navarro J, Chorro FJ, Górriz JL, Sanchis J, Voors AA, Bayés-Genís A; IMPROVE-HF Investigators.

Am J Med. 2019 Aug 15. pii: S0002-9343(19)30685-0. doi: 10.1016/j.amjmed.2019.07.041. [Epub ahead of print]

PMID:
31422111
7.

Geographical location affects the levels and association of trimethylamine N-oxide with heart failure mortality in BIOSTAT-CHF: a post-hoc analysis.

Yazaki Y, Salzano A, Nelson CP, Voors AA, Anker SD, Cleland JG, Lang CC, Metra M, Samani NJ, Ng LL, Suzuki T.

Eur J Heart Fail. 2019 Jul 28. doi: 10.1002/ejhf.1550. [Epub ahead of print] No abstract available.

PMID:
31353762
8.

Trajectories of Changes in Renal Function in Patients with Acute Heart Failure.

Beldhuis IE, Streng KW, van der Meer P, Maaten JMT, O'Connor CM, Metra M, Dittrich HC, Ponikowski P, Cotter G, Cleland JGF, Davison BA, Givertz MM, Teerlink JR, Bloomfield DM, Voors AA, Damman K.

J Card Fail. 2019 Jul 15. pii: S1071-9164(19)30070-3. doi: 10.1016/j.cardfail.2019.07.004. [Epub ahead of print]

9.

The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure.

Santema BT, Chan MMY, Tromp J, Dokter M, van der Wal HH, Emmens JE, Takens J, Samani NJ, Ng LL, Lang CC, van der Meer P, Ter Maaten JM, Damman K, Dickstein K, Cleland JG, Zannad F, Anker SD, Metra M, van der Harst P, de Boer RA, van Veldhuisen DJ, Rienstra M, Lam CSP, Voors AA.

Clin Res Cardiol. 2019 Jul 1. doi: 10.1007/s00392-019-01513-y. [Epub ahead of print]

PMID:
31263996
10.

Differences in Clinical Profile and Outcomes of Low Iron Storage vs Defective Iron Utilization in Patients With Heart Failure: Results From the DEFINE-HF and BIOSTAT-CHF Studies.

Grote Beverborg N, van der Wal HH, Klip IT, Anker SD, Cleland J, Dickstein K, van Veldhuisen DJ, Voors AA, van der Meer P.

JAMA Cardiol. 2019 Jul 1;4(7):696-701. doi: 10.1001/jamacardio.2019.1739.

PMID:
31188392
11.

Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure.

Felker GM, Borentain M, Cleland JG, DeSouza MM, Kessler PD, O'Connor CM, Seiffert D, Teerlink JR, Voors AA, McMurray JJV.

Eur J Heart Fail. 2019 Aug;21(8):1022-1031. doi: 10.1002/ejhf.1504. Epub 2019 Jun 6.

PMID:
31168885
12.

Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.

Shah SJ, Voors AA, McMurray JJV, Kitzman DW, Viethen T, Bomfim Wirtz A, Huang E, Pap AF, Solomon SD.

JAMA. 2019 Jun 4;321(21):2101-2112. doi: 10.1001/jama.2019.6717.

PMID:
31162568
13.

Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology.

Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chioncel O, Cleland JGF, de Boer RA, Drexel H, Ben Gal T, Hill L, Jaarsma T, Jankowska EA, Anker MS, Lainscak M, Lewis BS, McDonagh T, Metra M, Milicic D, Mullens W, Piepoli MF, Rosano G, Ruschitzka F, Volterrani M, Voors AA, Filippatos G, Coats AJS.

Eur J Heart Fail. 2019 May 26. doi: 10.1002/ejhf.1531. [Epub ahead of print]

PMID:
31129923
14.

Treating Heart Failure With Antihyperglycemic Medications: Is Now the Right Time?

Testani JM, Inzucchi SE, Voors AA.

Circulation. 2019 May 21;139(21):2383-2385. doi: 10.1161/CIRCULATIONAHA.119.038854. No abstract available.

PMID:
31107618
15.

Rationale and Design of the VITALITY-HFpEF Trial.

Butler J, Lam CSP, Anstrom KJ, Ezekowitz J, Hernandez AF, O'Connor CM, Pieske B, Ponikowski P, Shah SJ, Solomon SD, Voors AA, Wu Y, Carvalho F, Bamber L, Blaustein RO, Roessig L, Armstrong PW.

Circ Heart Fail. 2019 May;12(5):e005998. doi: 10.1161/CIRCHEARTFAILURE.119.005998.

PMID:
31096775
16.

Proenkephalin, an Opioid System Surrogate, as a Novel Comprehensive Renal Marker in Heart Failure.

Emmens JE, Ter Maaten JM, Damman K, van Veldhuisen DJ, de Boer RA, Struck J, Bergmann A, Sama IE, Streng KW, Anker SD, Dickstein K, Lang CC, Metra M, Samani NJ, Ng LL, Voors AA.

Circ Heart Fail. 2019 May;12(5):e005544. doi: 10.1161/CIRCHEARTFAILURE.118.005544.

PMID:
31091993
17.

The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study.

Markousis-Mavrogenis G, Tromp J, Ouwerkerk W, Devalaraja M, Anker SD, Cleland JG, Dickstein K, Filippatos GS, van der Harst P, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, Zannad F, Zwinderman AH, Hillege HL, van Veldhuisen DJ, Kakkar R, Voors AA, van der Meer P.

Eur J Heart Fail. 2019 Aug;21(8):965-973. doi: 10.1002/ejhf.1482. Epub 2019 May 14.

PMID:
31087601
18.

Time to Revisit the Value of Urine Collections in Heart Failure.

Ter Maaten JM, Voors AA.

JACC Heart Fail. 2019 May;7(5):392-393. doi: 10.1016/j.jchf.2019.01.015. No abstract available.

PMID:
31047018
19.

Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF.

Grodin JL, Liebo MJ, Butler J, Metra M, Felker GM, Hernandez AF, Voors AA, McMurray JJ, Armstrong PW, O'Connor C, Starling RC, Troughton RW, Tang WHW.

J Card Fail. 2019 Sep;25(9):703-711. doi: 10.1016/j.cardfail.2019.04.002. Epub 2019 Apr 4.

PMID:
30953792
20.

Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure.

Ter Maaten JM, Kremer D, Demissei BG, Struck J, Bergmann A, Anker SD, Ng LL, Dickstein K, Metra M, Samani NJ, Romaine SPR, Cleland J, Girerd N, Lang CC, van Veldhuisen DJ, Voors AA.

Eur J Heart Fail. 2019 Jun;21(6):732-743. doi: 10.1002/ejhf.1437. Epub 2019 Mar 6.

PMID:
30843353
21.

Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation.

Mordi IR, Santema BT, Kloosterman M, Choy AM, Rienstra M, van Gelder I, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Metra M, Ng LL, Ouwerkerk W, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Zannad F, Voors AA, Lang CC.

Clin Res Cardiol. 2019 Jul;108(7):797-805. doi: 10.1007/s00392-018-1409-x. Epub 2019 Jan 4.

22.

Rapid right-sided deterioration in heart failure with preserved ejection fraction.

Gorter TM, van Veldhuisen DJ, Voors AA.

Eur Heart J. 2019 Feb 21;40(8):699-702. doi: 10.1093/eurheartj/ehy900. No abstract available.

PMID:
30608519
23.

Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease.

Beldhuis IE, Myhre PL, Claggett B, Damman K, Fang JC, Lewis EF, O'Meara E, Pitt B, Shah SJ, Voors AA, Pfeffer MA, Solomon SD, Desai AS.

JACC Heart Fail. 2019 Jan;7(1):25-32. doi: 10.1016/j.jchf.2018.10.017.

PMID:
30606484
24.

Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSTAT-CHF study.

Ferreira JP, Metra M, Anker SD, Dickstein K, Lang CC, Ng L, Samani NJ, Cleland JG, van Veldhuisen DJ, Voors AA, Zannad F.

Eur J Heart Fail. 2019 Feb;21(2):218-226. doi: 10.1002/ejhf.1380. Epub 2019 Jan 1.

PMID:
30600578
25.

Adrenomedullin in heart failure: pathophysiology and therapeutic application.

Voors AA, Kremer D, Geven C, Ter Maaten JM, Struck J, Bergmann A, Pickkers P, Metra M, Mebazaa A, Düngen HD, Butler J.

Eur J Heart Fail. 2019 Feb;21(2):163-171. doi: 10.1002/ejhf.1366. Epub 2018 Dec 28. Review.

26.

Novel endotypes in heart failure: effects on guideline-directed medical therapy.

Tromp J, Ouwerkerk W, Demissei BG, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Zwinderman AH, Voors AA, van der Meer P.

Eur Heart J. 2018 Dec 21;39(48):4269-4276. doi: 10.1093/eurheartj/ehy712.

PMID:
30551207
27.

Discussion forum response to Canepa et al.

Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ.

Eur Heart J. 2019 Feb 21;40(8):705-706. doi: 10.1093/eurheartj/ehy796. No abstract available.

PMID:
30500882
28.

Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction.

Streng KW, Nauta JF, Hillege HL, Anker SD, Cleland JG, Dickstein K, Filippatos G, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Zannad F, Damman K, van der Meer P, Voors AA.

Int J Cardiol. 2018 Nov 15;271:132-139. doi: 10.1016/j.ijcard.2018.04.001. Epub 2018 Jul 7.

29.

Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure.

Cao TH, Jones DJL, Quinn PA, Chan DCS, Hafid N, Parry HM, Mohan M, Sandhu JK, Anker SD, Cleland JG, Dickstein K, Filippatos G, Hillege HL, Metra M, Ponikowski P, Samani NJ, Van Veldhuisen DJ, Zannad F, Zwinderman AH, Voors AA, Lang CC, Ng LL.

Clin Proteomics. 2018 Nov 2;15:35. doi: 10.1186/s12014-018-9213-1. eCollection 2018.

30.

Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure: results from BIOSTAT-CHF.

Suzuki T, Yazaki Y, Voors AA, Jones DJL, Chan DCS, Anker SD, Cleland JG, Dickstein K, Filippatos G, Hillege HL, Lang CC, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Zwinderman AH, Metra M, Ng LL.

Eur J Heart Fail. 2019 Jul;21(7):877-886. doi: 10.1002/ejhf.1338. Epub 2018 Oct 29.

PMID:
30370976
31.

Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points.

Greene SJ, Hernandez AF, Sun JL, Butler J, Armstrong PW, Ezekowitz JA, Zannad F, Ferreira JP, Coles A, Metra M, Voors AA, Califf RM, O'Connor CM, Mentz RJ.

Circ Cardiovasc Qual Outcomes. 2018 Oct;11(10):e004783. doi: 10.1161/CIRCOUTCOMES.118.004783.

PMID:
30354576
32.

Treating oxidative stress in heart failure: past, present and future.

van der Pol A, van Gilst WH, Voors AA, van der Meer P.

Eur J Heart Fail. 2019 Apr;21(4):425-435. doi: 10.1002/ejhf.1320. Epub 2018 Oct 19. Review.

33.

Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study.

Ferreira JP, Metra M, Mordi I, Gregson J, Ter Maaten JM, Tromp J, Anker SD, Dickstein K, Hillege HL, Ng LL, van Veldhuisen DJ, Lang CC, Voors AA, Zannad F.

Eur J Heart Fail. 2019 Jan;21(1):112-120. doi: 10.1002/ejhf.1323. Epub 2018 Oct 19.

PMID:
30338883
34.

Markers of left ventricular systolic dysfunction when left ventricular ejection fraction is normal.

Nauta JF, Jin X, Hummel YM, Voors AA.

Eur J Heart Fail. 2018 Dec;20(12):1636-1638. doi: 10.1002/ejhf.1326. Epub 2018 Oct 17. Review. No abstract available.

PMID:
30328663
35.

What is the added value of the waist-to-hip ratio on top of the BIOSTAT risk prediction model in patients with heart failure? Reply.

Streng KW, Lang CC, Voors AA.

Eur J Heart Fail. 2019 Jan;21(1):132-133. doi: 10.1002/ejhf.1324. Epub 2018 Oct 8. No abstract available.

36.

Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction.

Voors AA, Shah SJ, Bax JJ, Butler J, Gheorghiade M, Hernandez AF, Kitzman DW, McMurray JJV, Wirtz AB, Lanius V, van der Laan M, Solomon SD.

Eur J Heart Fail. 2018 Nov;20(11):1601-1610. doi: 10.1002/ejhf.1295. Epub 2018 Sep 17.

PMID:
30225882
37.

Very Early Diuretic Response After Admission for Acute Heart Failure.

Kuroda S, Damman K, Ter Maaten JM, Voors AA, Okumura T, Kida K, Oishi S, Akiyama E, Suzuki S, Yamamoto M, Kitai T, Yoshida K, Matsumura A, Matsue Y.

J Card Fail. 2019 Jan;25(1):12-19. doi: 10.1016/j.cardfail.2018.09.004. Epub 2018 Sep 13.

PMID:
30219549
38.

Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF).

Fudim M, Parikh KS, Dunning A, DeVore AD, Mentz RJ, Schulte PJ, Armstrong PW, Ezekowitz JA, Tang WHW, McMurray JJV, Voors AA, Drazner MH, O'Connor CM, Hernandez AF, Patel CB.

Am J Cardiol. 2018 Nov 1;122(9):1506-1512. doi: 10.1016/j.amjcard.2018.07.023. Epub 2018 Aug 3.

PMID:
30172362
39.

Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction.

Tromp J, Westenbrink BD, Ouwerkerk W, van Veldhuisen DJ, Samani NJ, Ponikowski P, Metra M, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Lang CC, Ng LL, Zannad F, Zwinderman AH, Hillege HL, van der Meer P, Voors AA.

J Am Coll Cardiol. 2018 Sep 4;72(10):1081-1090. doi: 10.1016/j.jacc.2018.06.050.

40.

Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction.

Santema BT, Kloosterman M, Van Gelder IC, Mordi I, Lang CC, Lam CSP, Anker SD, Cleland JG, Dickstein K, Filippatos G, Van der Harst P, Hillege HL, Ter Maaten JM, Metra M, Ng LL, Ponikowski P, Samani NJ, Van Veldhuisen DJ, Zwinderman AH, Zannad F, Damman K, Van der Meer P, Rienstra M, Voors AA.

Eur Heart J. 2018 Nov 14;39(43):3867-3875. doi: 10.1093/eurheartj/ehy421.

41.

Plasma levels of heart failure biomarkers are primarily a reflection of extracardiac production.

Du W, Piek A, Schouten EM, van de Kolk CWA, Mueller C, Mebazaa A, Voors AA, de Boer RA, Silljé HHW.

Theranostics. 2018 Jul 30;8(15):4155-4169. doi: 10.7150/thno.26055. eCollection 2018.

42.

A comparison of the prognostic value of BNP versus NT-proBNP after hospitalisation for heart failure.

Linssen GCM, Jaarsma T, Hillege HL, Voors AA, van Veldhuisen DJ.

Neth Heart J. 2018 Oct;26(10):486-492. doi: 10.1007/s12471-018-1145-x.

43.

OPLAH ablation leads to accumulation of 5-oxoproline, oxidative stress, fibrosis, and elevated fillings pressures: a murine model for heart failure with a preserved ejection fraction.

van der Pol A, Gil A, Tromp J, Silljé HHW, van Veldhuisen DJ, Voors AA, Hoendermis ES, Grote Beverborg N, Schouten EM, de Boer RA, Bischoff R, van der Meer P.

Cardiovasc Res. 2018 Dec 1;114(14):1871-1882. doi: 10.1093/cvr/cvy187.

PMID:
30032247
44.

Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial.

Grodin JL, Butler J, Metra M, Felker GM, Voors AA, McMurray JJ, Armstrong PW, Hernandez AF, O'Connor C, Starling RC, Tang WHW.

J Card Fail. 2018 Aug;24(8):512-519. doi: 10.1016/j.cardfail.2018.06.008.

PMID:
30012361
45.

Waist-to-hip ratio and mortality in heart failure.

Streng KW, Voors AA, Hillege HL, Anker SD, Cleland JG, Dickstein K, Filippatos G, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Zannad F, Damman K, van der Meer P, Lang CC.

Eur J Heart Fail. 2018 Sep;20(9):1269-1277. doi: 10.1002/ejhf.1244. Epub 2018 Jul 2.

46.

Bio-adrenomedullin as a potential quick, reliable, and objective marker of congestion in heart failure.

Kremer D, Ter Maaten JM, Voors AA.

Eur J Heart Fail. 2018 Sep;20(9):1363-1365. doi: 10.1002/ejhf.1245. Epub 2018 Jun 22. No abstract available.

47.

Heart failure with preserved ejection fraction: from mechanisms to therapies.

Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ.

Eur Heart J. 2018 Aug 7;39(30):2780-2792. doi: 10.1093/eurheartj/ehy301.

PMID:
29905796
49.

Sex-specific associations of obesity and N-terminal pro-B-type natriuretic peptide levels in the general population.

Suthahar N, Meijers WC, Ho JE, Gansevoort RT, Voors AA, van der Meer P, Bakker SJL, Heymans S, van Empel V, Schroen B, van der Harst P, van Veldhuisen DJ, de Boer RA.

Eur J Heart Fail. 2018 Aug;20(8):1205-1214. doi: 10.1002/ejhf.1209. Epub 2018 Jun 1.

50.

Prognostic Significance of Creatinine Increases During an Acute Heart Failure Admission in Patients With and Without Residual Congestion: A Post Hoc Analysis of the PROTECT Data.

Metra M, Cotter G, Senger S, Edwards C, Cleland JG, Ponikowski P, Cursack GC, Milo O, Teerlink JR, Givertz MM, O'Connor CM, Dittrich HC, Bloomfield DM, Voors AA, Davison BA.

Circ Heart Fail. 2018 May;11(5):e004644. doi: 10.1161/CIRCHEARTFAILURE.117.004644.

PMID:
29748350

Supplemental Content

Loading ...
Support Center